EU, US & Japan Tackle Difficulties With Randomized Trials Involving Multi-Drug Resistant Bacteria

 
• By Neena Brizmohun

The European Medicines Agency has given the Pink Sheet more detail on its recent agreement with its counterparts in the US and Japan to align certain clinical data requirement to stimulate the development of new treatments to fight antimicrobial resistance.

Streamlined
Aligned EU, US and Japanese trial data requirements should stimulate antibiotic development • Source: Shutterstock

More from Clinical Trials

More from R&D